Skip to main content

Advertisement

SpringerLink
Log in

Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Introduction

Older people aged over 75 are more prone to falls because physical functions become deteriorated along with aging, and also fracture risk is strongly correlated with age. We evaluated the effects of anti-osteoporosis agents, eldecalcitol (ELD) and alendronate (ALN) on physical functions by assessing dynamic and static postural balance in aged patients with osteoporosis.

Materials and methods

A randomized, open-label, controlled clinical trial has been conducted with 124 female patients aged 65 or over with osteoporosis. Patients were randomly assigned to receive either 0.75 μg of ELD once-a-day or 35 mg of ALN once-a-week for 24 weeks. The primary endpoint was the change in a postural balance index, adjusted composite equilibrium score (CES) of sensory organization test (SOT). The SOT equilibrium scores, leg muscle strength, and other physical functions were also evaluated.

Results

The Adjusted CES increased from baseline by 6.10% in the ELD group and 6.28% in the ALN group. There was no statistically significant difference between the two groups. The static postural balance at fixed platform were maintained in the ELD group, but declined in the ALN group. The dynamic postural balance at swaying platform and knee extension power increased from baseline in both groups.

Conclusions

These results suggest that ELD and ALN treatments may each be beneficial to improve postural balance control in older patients with osteoporosis via different mechanisms of action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Suzuki T, Kwon JH, Kim HK et al (2008) Low serum 25-hydroxyvitamin D levels associated with falls among Japanese community-dwelling elderly. J Bone Miner Res 23:1309–1317

    Article  CAS  PubMed  Google Scholar 

  2. Todd C, Skelton D. What are the main risk factors for falls among older people and what are the most effective interventions to prevent these falls? Copenhagen, WHO Regional Office for Europe (Health Evidence Network report). https://www.euro.who.int/document/E82552.pdf. Accessed on 20 Dec 2018.

  3. Wihlborg A, Englund M, Åkesson K, Gerdhem P (2015) Fracture predictive ability of physical performance tests and history of falls in elderly women: a 10-year prospective study. Osteoporos Int 26:2101–2109

    Article  CAS  PubMed  Google Scholar 

  4. Buatois S, Gueguen R, Gauchard GC et al (2006) Posturography and risk of recurrent falls in healthy non-institutionalized persons aged over 65. Gerontology 52:345–352

    Article  PubMed  Google Scholar 

  5. Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124

    Article  CAS  PubMed  Google Scholar 

  6. Kawate H, Ohnaka K, Adachi M et al (2010) Alendronate improves QOL of postmenopausal women with osteoporosis. Clin Interv Aging 5:123–131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kamatari M, Koto S, Ozawa N et al (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302–309

    Article  CAS  PubMed  Google Scholar 

  8. Johnell O, Jönsson B, Jönsson L, Black D (2003) Cost effectiveness of alendronate (Fosamax®) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314

    Article  PubMed  Google Scholar 

  9. Matsumoto T, Ito M, Hayashi Y et al (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures—a randomized, active comparator, double-blind study. Bone 49:605–612

    Article  CAS  PubMed  Google Scholar 

  10. Uenishi K, Tokiwa M, Kato S, Shiraki M (2018) Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis. Osteoporos Int 29:723–732

    Article  CAS  PubMed  Google Scholar 

  11. Kwon J, Suzuki T, Yoshida H et al (2007) Concomitant lower serum albumin and vitamin D levels are associated with decreased objective physical performance among Japanese community-dwelling elderly. Gerontology 53:322–328

    Article  CAS  PubMed  Google Scholar 

  12. Pfeifer M, Begerow B, Minne HW et al (2001) Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 109:87–92

    Article  CAS  PubMed  Google Scholar 

  13. Lagari V, Gómez-Marín O, Levis S (2013) The role of vitamin D in improving physical performance in the elderly. J Bone Miner Res 28:2194–2201

    Article  CAS  PubMed  Google Scholar 

  14. Kenny AM, Biskup B, Robbins B et al (2003) Effects of vitamin D supplementation on strength, physical function, and health perception in older, community-dwelling men. J Am Geriatr Soc 51:1762–1767

    Article  PubMed  Google Scholar 

  15. Pfeifer M, Begerow B, Minne HW et al (2009) Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int 20:315–322

    Article  CAS  PubMed  Google Scholar 

  16. Bogaerts A, Delecluse C, Boonen S et al (2011) Changes in balance, functional performance and fall risk following whole body vibration training and vitamin D supplementation in institutionalized elderly women. A 6 month randomized controlled trial. Gait Posture 33:466–472

    Article  PubMed  Google Scholar 

  17. Dhesi JK, Jackson SH, Bearne LM et al (2004) Vitamin D supplementation improves neuromuscular function in older people who fall. Age Ageing 33:589–595

    Article  PubMed  Google Scholar 

  18. Vouriot A, Gauchard GC, Chaua N et al (2004) Sensorial organisation favouring higher visual contribution is a risk factor of falls in an occupational setting. Neurosci Res 48:239–247

    Article  PubMed  Google Scholar 

  19. Zammit G, Wang-Weigand S, Peng X (2008) Use of computerized dynamic posturography to assess balance in older adults after nighttime awakenings using zolpidem as a reference. BMC Geriatr 8:15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Carter ND, Khan KM, McKay HA et al (2002) Community-based exercise program reduces risk factors for falls in 65–75-year-old women with osteoporosis: randomized controlled trial. CMAJ 167:997–1004

    PubMed  PubMed Central  Google Scholar 

  21. DiFrancisco-Donoghue J, Jung MK, Geisel P, Werner WG (2015) Learning effects of the sensory organization test as a measure of postural control and balance in Parkinson’s disease. Parkinsonism Relat Disord 21:858–861

    Article  PubMed  Google Scholar 

  22. Podsiadlo D, Richardson S (1991) The timed “Up and Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39:142–148

    Article  CAS  PubMed  Google Scholar 

  23. Saito K, Miyakoshi N, Matsunaga T et al (2016) Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study. J Bone Miner Metab 34:547–554

    Article  CAS  PubMed  Google Scholar 

  24. Iwamoto J, Sato Y (2014) Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates. Ther Clin Risk Manag 10:51–59

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hagino H, Yamamoto T, Miyakoshi H et al (2010) The effect of active vitamin D3 on fall-related physical function in patients with osteoporosis. Osteoporos Jpn 18:309–313

    Google Scholar 

  26. Bolland MJ, Grey A, Gamble GD, Reid IR (2014) Vitamin D supplementation and falls: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2:573–580

    Article  CAS  PubMed  Google Scholar 

  27. Uusi-Rasi K, Patil R, Karinkanta S et al (2015) Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. JAMA Intern Med 175:703–711

    Article  PubMed  Google Scholar 

  28. Glendenning P, Zhu K, Inderjeeth C et al (2012) Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. J Bone Miner Res 27:170–176

    Article  CAS  PubMed  Google Scholar 

  29. Cangussu LM, Nahas-Neto J, Orsatti CL et al (2015) Effect of vitamin D supplementation alone on muscle function in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial. Osteoporos Int 26:2413–2421

    Article  CAS  PubMed  Google Scholar 

  30. Cangussu LM, Nahas-Neto J, Orsatti CL et al (2016) Effect of isolated vitamin D supplementation on the rate of falls and postural balance in postmenopausal women fallers: a randomized, double-blind, placebo-controlled trial. Menopause 23:267–274

    Article  PubMed  Google Scholar 

  31. Harvey NC, Biver E, Kaufman JM et al (2017) The role of calcium supplementation in healthy musculoskeletal ageing: an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int 28:447–462

    Article  CAS  PubMed  Google Scholar 

  32. Verschueren SM, Bogaerts A, Delecluse C et al (2011) The effects of whole-body vibration training and vitamin D supplementation on muscle strength, muscle mass, and bone density in institutionalized elderly women: a 6-month randomized, controlled trial. J Bone Miner Res 26:42–49

    Article  CAS  PubMed  Google Scholar 

  33. Beaudart C, Buckinx F, Rabenda V et al (2014) The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 99:4336–4345

    Article  CAS  PubMed  Google Scholar 

  34. Yoshioka T, Okimoto N, Okamoto K, Sakai A (2013) A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients. J Bone Miner Metab 31:153–160

    Article  CAS  PubMed  Google Scholar 

  35. Nevitt MC, Thompson DE, Black DM et al (2000) Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 160:77–85

    Article  CAS  PubMed  Google Scholar 

  36. Schelldorfer S, Ernst MJ, Rast FM et al (2015) Low back pain and postural control, effects of task difficulty on centre of pressure and spinal kinematics. Gait Posture 41:112–118

    Article  PubMed  Google Scholar 

  37. Chiu HC, Chiu CY, Yang RS et al (2018) Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. J Cachexia Sarcopenia Muscle 9:585–602

    Article  PubMed  PubMed Central  Google Scholar 

  38. Harada A, Ito S, Matsui Y et al (2015) Effect of alendronate on muscle mass: investigation in patients with osteoporosis. Osteoporos Sarcopenia 1:53–58

    Article  Google Scholar 

Download references

Acknowledgement

The authors thank the members of the EFFECT Study Group: Tokuhisa Kanbara, Hideoki Matsuoka, Mitsuo Mitani, Akira Okamoto, Takashi Sato, and Chihiro Tanaka. We also thank Satoshi Kondo for the preparation of the manuscript. The study was supported by Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd.

Funding

This work is funded by Chugai Pharmaceutical Co. Ltd., and Taisho Pharmaceutical Co. Ltd (JapicCTI-No. 122013).

Author information

Authors and Affiliations

  1. Institute of Gerontology, J. F. Oberlin University, 3758 Tokiwa-machi, Machida, 194-0294, Tokyo, Japan

    Takao Suzuki

  2. Department of Orthopedic Surgery, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan

    Atsushi Harada

  3. Department of Preventive Gerontology, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan

    Hiroyuki Shimada

  4. Kenkoin Clinic, Tokyo, Japan

    Takayuki Hosoi

  5. Chugai Pharmaceutical Co. Ltd., Tokyo, Japan

    Yuichi Kawata & Hitoshi Saito

  6. Taisho Pharmaceutical Co. Ltd., Tokyo, Japan

    Tomoyuki Inoue

Authors
  1. Takao Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsushi Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroyuki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takayuki Hosoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuichi Kawata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoyuki Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hitoshi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All the authors have equally contributed to the study. TS, AH, HSh, TH, YK, TI and HSa designed the study, contributed to the implementation, prepared the draft of the paper, and approved the final version.

Corresponding author

Correspondence to Takao Suzuki.

Ethics declarations

Conflicts of interest

TS has received personal fees and non-financial support from Chugai Pharmaceutical Co. Ltd., during the conduct of the study. AH and HSh has nothing to disclose. TH reports personal fees from Daiichi Sankyo Co. Ltd., personal fees from Ono Pharmaceutical Co. Ltd., and personal fees from Pfizer Japan Inc., outside of the submitted work. YK and HSa are employees of Chugai Pharmaceutical Co. Ltd. TI is an employee of Taisho Pharmaceutical Co. Ltd.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, T., Harada, A., Shimada, H. et al. Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis. J Bone Miner Metab 38, 859–867 (2020). https://doi.org/10.1007/s00774-020-01118-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-020-01118-w

Keywords

Search

Navigation